Skip to main content

Videos

Videos

ArteraAI Offers a New Approach to Breast Cancer Treatment Decision-Making

Matthew Kurian, MD, examines ArteraAI Breast, a newly FDA-cleared multimodal platform that combines pathology imaging and cli [...]

Watch this video

Videos

CHHiP Trial Evaluates a Multimodal AI Biomarker in Localized Prostate Cancer – Anna Wilkins

Anna Wilkins describes her validation of the Artera MMAI biomarker, drawing on over 2,000 biopsies from the 3,200-patient CHH [...]

Watch this video

Videos

CHHiP Trial Analysis: Prognostic, Risk Stratification Value of MMAI Model for Localized Prostate Cancer

Anna Wilkins, PhD, of Royal Marsden Hospital Institute of Cancer Research (UK), details an external validation of a digital p [...]

Watch this video

Videos

Study Investigates an AI-Powered Prognostic Test in Salvage Radiation Therapy Patients – Paul Nguyen

Paul Nguyen discusses the Artera AI prostate test for post-prostatectomy BCR. The test combines clinical factors with AI-anal [...]

Watch this video

Videos

Daniel Spratt, MD, on using ArteraAI to guide salvage therapy decisions

On December 9, 2025, Artera announced the commercial launch of the ArteraAI Prostate Test (Post-RP), a tool designed to help [...]

Watch this video

Videos

Melvin L.K. Chua, FRCR, PhD, FASCO, on validation of an MMAI model in Asian patients

Data presented at the American Society for Radiation Oncology 67th Annual Meeting validated the performance of the ArteraAI P [...]

Watch this video

Videos

AI Tools Speed Prostate Cancer Decisions With Faster Results

FDA-authorized artificial intelligence (AI) tools have the potential to help patients with prostate cancer get clearer answer [...]

Watch this video

Videos

AI Model Identifies STAMPEDE Patients Needing Treatment Intensification – Nicholas James

Zachary Klaassen interviews Nicholas James about applying the ArteraAI prostate test to high-risk M0 prostate cancer patients [...]

Watch this video

Videos

AI News: Artera presented data at #ASCO25 showing that its AI platform can identify prostate cancer patients most likely to benefit (or not benefit) from added androgen receptor inhibitor therapy

CMO Tim Showalter describes the finding, which was selected as a "Best of ASCO" oral presentation. Plus, helping to determine [...]

Watch this video

1 2 3 5